Published Data in Metastatic Ocular Melanoma
SIR-Spheres® Y-90 resin microspheres have shown benefits in the first-line treatment of treatment-refractory liver metastases from melanoma (predominantly from ocular or uveal primary tumours).
In a mixed population of patients with unresectable cutaneous or ocular metastatic melanoma that was refractory to systemic therapy, SIR-Spheres Y-90 resin microspheres were associated with longer survival from diagnosis of the metastatic melanoma than best supportive care (19.9 months vs. 4.8 months).1 Other non-comparative studies of SIRT with SIR-Spheres Y-90 resin microspheres for metastatic melanoma have demonstrated similar or longer survival from diagnosis (19.0–23.9 months).2,3
SIR-Spheres Y-90 resin microspheres are generally well tolerated in this clinical setting.
1 Xing M. et al. Am J Clin Oncol 2014 Aug 1; ePub doi: 10.1097/COC.0000000000000109.
2 Klingenstein A. et al. Cardiovasc Intervent Radiol 2013; 36: 158-165.
3 Eldredge-Hindy H. et al. Am J Clin Oncol 2016; 39: 189-195.